18F-BMS-986229 Injection + IV 18F-BMS-986229
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
22
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Esophagogastric Cancer
Conditions
Esophagogastric Cancer, Esophagus Cancer, Esophageal Cancer, Gastric Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Gastroesophageal Junction Squamous Cell Carcinoma
Trial Timeline
Nov 12, 2019 → Mar 6, 2024
NCT ID
NCT04161781About 18F-BMS-986229 Injection + IV 18F-BMS-986229
18F-BMS-986229 Injection + IV 18F-BMS-986229 is a pre-clinical stage product being developed by Bristol Myers Squibb for Esophagogastric Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT04161781. Target conditions include Esophagogastric Cancer, Esophagus Cancer, Esophageal Cancer.
Hype Score Breakdown
Clinical
5
Activity
2
Company
9
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04161781 | Pre-clinical | Completed |
Competing Products
6 competing products in Esophagogastric Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Trastuzumab deruxtecan + 5FU/LV + Trastuzumab deruxtecan + FLO | Daiichi Sankyo | Phase 1/2 | 41 |
| Pembrolizumab + Trastuzumab + FLOT | Merck | Phase 2 | 52 |
| bevacizumab + capecitabine + cisplatin + Epirubicin + Lapatinib | Roche | Phase 2/3 | 65 |
| Capecitabine + Epirubicin + AMG 102 + Cisplatin + Placebo | Amgen | Phase 1/2 | 40 |
| Sacituzumab govitecan | Gilead Sciences | Phase 1/2 | 40 |
| regorafenib + nivolumab + FOLFOX chemotherapy with oxaliplatin | Bristol Myers Squibb | Phase 2 | 51 |